Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

Boston Scientific, Inc. (BSX) recently gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (“PFA”) system, which is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation. The system represents a unique new alternative to standard-of-care thermal ablation treatment.Addressing the vast population living with paroxysmal atrial fibrillation (AF), the approval offers an incredible opportunity t ...